Thymidylate synthase, Dihydrofolate reductase, and DNA (Pemetrexed and Oxaliplatin targets) (TS/DHFR/DNA)

The combination of pemetrexed and oxaliplatin targets a critical intersection of metabolic and structural pathways within cancer cells. Pemetrexed is a multi-targeted antifolate that inhibits three key enzymes in folate metabolism: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) [FDA Alimta Label, 2022]. This inhibition starves the cell of thymidine and purine nucleotides, effectively halting de novo DNA and RNA synthesis [PubChem CID 135398510]. Concurrently, oxaliplatin acts as a DNA-damaging agent by forming bulky platinum-DNA adducts, a process referred to as DNA platination [StatPearls, 2023]. These adducts create physical barriers to DNA polymerase and RNA polymerase, leading to cell cycle arrest and the induction of programmed cell death [PubChem CID 43805]. The therapeutic rationale for this combination lies in the potential for pemetrexed-induced nucleotide depletion to enhance the efficacy of oxaliplatin by interfering with the cell's ability to repair platinum-induced DNA damage [Journal of Clinical Oncology, 2005]. This dual-action approach is a standard consideration in the treatment of advanced solid tumors, particularly non-small cell lung cancer and mesothelioma [National Cancer Institute, 2023].

Other names

Pemetrexed and Oxaliplatin combination targetsAntifolate and Platinum adduct synergyTS/DHFR/GARFT and DNA platinationPEM/OX target complex

Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), leading to the depletion of nucleotide pools required for DNA synthesis. Oxaliplatin undergoes intracellular conversion to reactive platinum derivatives that bind to DNA, forming intra-strand and inter-strand cross-links (DNA platination). The combination results in synergistic cytotoxicity by simultaneously inhibiting DNA precursor production and inducing structural DNA damage that triggers apoptosis.